Blinatumomab,Inotuzumab Ozogamicin
amgen,Pfizer,UCB pharmaceuticals
['leusm', 'leukemia', 'blinatumomab', 'inotuzumab', 'inotuzumab ozogamicin']
#eha2023 exciting data &amp; new regimen for older pts with b-all mini-hyper-cvd + inotuzumab ozogamicin blinatumomab: 5-yr os = 48%. combination was well tolerated, no early deaths
#allsm #leusm #leukemia 
Assistant Professor, 
Leukemia Department                                                                 
MD Anderson Cancer Center, Houston